For most men with localized prostate cancer, proton therapy and conventional photon-based radiation produce nearly identical cancer control rates and quality-of-life outcomes. The first large randomized trial directly comparing the two, called PARTIQoL, found no measurable difference in bowel, urinary, or sexual function at any time point out to five years, and no difference in tumor control. That result surprised many patients and clinicians who expected the physics advantages of protons to translate into clear clinical wins. The reality is more nuanced than either “protons are superior” or “they’re the same,” and it depends heavily on which outcomes you care about and how long you follow patients.
What Makes Proton Therapy Physically Different
Both proton therapy and conventional radiation (which uses photon beams, typically delivered as intensity-modulated radiation therapy, or IMRT) aim to kill cancer cells by damaging their DNA. The key physical difference is how the energy is deposited in the body. A photon beam enters the body, deposits dose continuously as it passes through tissue, and exits out the other side. A proton beam enters the body, deposits relatively little dose along the way, then dumps most of its energy at a specific depth before stopping abruptly. That spike of energy deposition is called the Bragg peak, and it means the tissue beyond the target receives almost no radiation at all.
On paper, this is a compelling advantage. For a tumor sitting next to the rectum and bladder, being able to stop the beam right at the tumor’s edge should spare those organs. Planning studies consistently show that proton plans deliver lower doses to surrounding healthy tissue. But whether that dosimetric advantage translates into fewer side effects or better cancer outcomes for prostate cancer specifically has been the subject of intense debate for more than a decade. The prostate sits deep in the pelvis, surrounded by organs that shift position from day to day and even during a single treatment session, and this complicates the precision that protons theoretically offer.
The PARTIQoL Trial Changed the Conversation
PARTIQoL was a multi-center, phase III randomized trial that enrolled men with low- or intermediate-risk prostate cancer and randomly assigned them to either proton therapy or IMRT. The primary question was whether proton therapy produced better patient-reported bowel quality of life at 24 months. The answer was no. Both groups showed only a small, clinically insignificant decline in bowel scores from baseline, and the difference between arms was not statistically significant. The same held true for urinary function, sexual function, and hormonal symptoms at every time point measured, from 3 months all the way out to 60 months. Progression-free survival was also equivalent, at about 93% for both groups at five years.
This trial carries substantial weight because it is the only completed randomized comparison. Most prior evidence came from retrospective studies that compared proton-treated patients with IMRT-treated patients using medical records, which introduces selection bias: men who seek out proton therapy tend to be younger, healthier, and more affluent, making it hard to disentangle the treatment effect from the patient effect. PARTIQoL sidesteps that problem through randomization.
Where Retrospective Data Tells a Different Story
Not all the evidence lines up so neatly. A single-institution retrospective analysis from Japan compared proton beam therapy with IMRT using propensity-score matching and found significantly higher seven-year biochemical relapse-free survival with protons: about 99% versus 90% in the matched cohort. Disease-free survival also favored protons in that analysis. The gap was especially pronounced in intermediate-risk patients.
How do you square that with PARTIQoL? Retrospective single-institution studies are inherently less reliable than randomized trials, and differences in patient selection, dose prescriptions, and institutional expertise can all influence results. The Japanese study also used different risk stratification and follow-up conventions. It is a signal worth noting but not strong enough on its own to overturn the randomized data. When a well-conducted randomized trial and a retrospective analysis disagree, the randomized trial gets more weight. That said, the longer follow-up in the retrospective data (seven years versus five) does raise the possibility that differences might emerge over a longer horizon.
Side Effects Are More Complicated Than a Simple Winner
The side-effect picture from the broader literature is messy, in part because different studies measure toxicity differently and follow patients for different lengths of time. An updated claims-based analysis of a large U.S. cohort found no statistically significant difference in gastrointestinal or genitourinary toxicity between IMRT and proton therapy at 6, 12, or 24 months. A matched-pair European study similarly found no significant differences in most toxicity categories, though it did report significantly lower rates of late urinary urgency with proton therapy.
One study of younger men painted a more mixed picture. It found that proton therapy was associated with lower rates of urinary toxicity and erectile dysfunction at two years, but a higher rate of bowel toxicity compared with IMRT. That last finding is counterintuitive given protons’ theoretical rectal sparing, but it may reflect the sensitivity of the anterior rectal wall to the Bragg peak’s sharp dose falloff, which, if slightly misplaced due to daily anatomical variation, can deposit a high dose right where it was supposed to spare tissue. In the postoperative setting, where men receive radiation after prostatectomy, a separate study found no difference in either gastrointestinal or genitourinary toxicity between the two modalities.
Patient-reported outcomes studies have added another layer. One comparative effectiveness study that directly asked patients about their symptoms found no differences in bowel, urinary incontinence, urinary irritation, or sexual function between proton and IMRT cohorts, aligning closely with PARTIQoL’s findings.
Sexual Function After Proton Therapy
Erectile function is a major concern for men choosing a treatment for prostate cancer, and proton therapy has sometimes been marketed with the suggestion that it better preserves potency. The data is thin. One long-term follow-up study of younger men treated with proton therapy reported that potency (defined as erections firm enough for intercourse) was 90% at baseline, dropped to 72% at one year, and settled at 67% at five years. Those are reasonable numbers for radiation therapy in general, but without a randomized comparison arm they do not tell you whether IMRT would have done worse.
A modeling study concluded that proton-based stereotactic body radiation therapy might offer better erectile function preservation in younger, previously potent men compared with photon approaches, but that conclusion rested on assumptions rather than direct clinical measurement. PARTIQoL, which did have a direct comparison arm, found no difference in sexual function scores at any time point. The honest assessment is that neither modality has proven itself superior for sexual function preservation in head-to-head testing.
The Secondary Cancer Question
One area where proton therapy does have a consistent theoretical and now increasingly empirical edge is the risk of developing a new cancer years after treatment. Because protons deliver less scatter radiation to tissues far from the target, the total radiation dose absorbed by the rest of the body is lower. Dosimetric modeling studies have estimated that proton therapy reduces the risk of a radiation-induced secondary malignancy by roughly 26% to 39% compared with IMRT, driven largely by lower doses to the rectum and bladder.
A large database study went beyond modeling and looked at actual secondary cancer rates. Compared with IMRT, proton therapy was associated with about half the odds of developing a secondary primary cancer (adjusted odds ratio of 0.49). Stereotactic body radiotherapy also showed a reduced risk compared with IMRT in that analysis, suggesting that the advantage may be tied to overall integral dose rather than something unique to protons. For a 70-year-old man whose remaining life expectancy is 10 to 15 years, the absolute risk reduction from fewer secondary cancers may be small. For a 55-year-old man who might live another 30 years, the argument for minimizing whole-body radiation exposure carries more weight.
When Proton Therapy Has a Clearer Physical Advantage
There are specific clinical situations where the physics of proton therapy matter more than they do for the average prostate cancer patient. One well-studied example is the presence of a metal hip prosthesis. Metal implants scatter and attenuate photon beams unpredictably, forcing radiation planners to work around the implant and sometimes accept suboptimal dose distributions. A dosimetric study showed that proton therapy, using lateral and oblique beam angles, could provide better target coverage and healthier-tissue sparing in these patients compared with photon-based approaches.
Similarly, men who need radiation to the pelvic lymph nodes in addition to the prostate (typically those with higher-risk disease) may benefit more from protons because the larger treatment volume increases the amount of bowel and bone marrow exposed to scatter radiation with photons. The evidence here is still emerging and comes mostly from planning comparisons rather than clinical outcome data, but the physical rationale is stronger when more tissue needs to be irradiated.
Rectal Spacers and the Narrowing Gap
One development that has blurred the line between proton and photon therapy is the rectal spacer, a hydrogel or biodegradable material injected between the prostate and the rectum before treatment. By physically pushing the rectum away from the high-dose zone, a spacer reduces rectal radiation exposure regardless of which beam type is used.
A study comparing proton therapy patients with and without a rectal spacer found that acute grade 1-2 gastrointestinal toxicity dropped from about 31% without a spacer to 6% with one. Late toxicity followed a similar pattern. A separate dosimetric comparison across multiple radiation techniques confirmed that the rectal spacer produced significant dose reductions for all modalities, but proton therapy combined with a spacer achieved the largest high-dose reduction to the rectum. Still, the spacer also dramatically improved photon-based plans, which means one of proton therapy’s key selling points, rectal sparing, can be partially replicated by adding a relatively simple procedure to an IMRT course. For a patient weighing the cost and logistics of proton therapy against IMRT with a spacer, this is a meaningful consideration.
The Cost Gap
Proton therapy is substantially more expensive than IMRT. The facilities cost hundreds of millions of dollars to build and maintain, and per-treatment charges are correspondingly higher. A cost-effectiveness analysis published in the Journal of Clinical Oncology concluded that even under the optimistic assumption that protons would allow a dose escalation of 10 Gray above what IMRT could deliver, proton therapy was not cost-effective for most prostate cancer patients using a standard willingness-to-pay threshold. The study of younger men that found some toxicity advantages for protons explicitly noted that those benefits came at nearly double the cost of IMRT. If the clinical outcomes are equivalent for the majority of patients, as PARTIQoL suggests, then the cost differential becomes hard to justify on a population level, even if individual patients value the potential for marginal side-effect differences.
Insurance coverage varies. In the United States, many insurers have pushed back against covering proton therapy for prostate cancer specifically because of the lack of demonstrated superiority in randomized trials. Some cover it, some deny it, and coverage decisions can change as new data emerge.
Motion, Uncertainty, and Why the Physics Do Not Always Win
A recurring theme in the proton-versus-photon debate for prostate cancer is the gap between what planning studies show on a computer screen and what happens inside a living, moving patient. The prostate shifts position between treatment sessions because of changes in rectal and bladder filling. It can also move during a session. Because proton beams stop at a precise depth, even small shifts in anatomy can move the Bragg peak off target, potentially underdosing the tumor or overdosing the rectum. Research on dosimetric uncertainty in proton prostate treatments has emphasized that variations in organ position relative to the sharp dose-falloff gradients must be accounted for when evaluating plans.
Photon beams, by contrast, are more forgiving of these shifts because their dose falls off gradually rather than abruptly. Modern proton centers mitigate this with daily image guidance and adaptive planning, but the sensitivity to motion remains a fundamental challenge. Hypofractionated schedules, which deliver larger doses per session over fewer visits, are increasingly popular for prostate cancer and can improve the therapeutic ratio because prostate tumors appear to be especially sensitive to large fraction sizes. However, the fewer fractions also mean each individual session carries more weight, and the consequences of a positional error are amplified. Research on interfractional motion during hypofractionated proton therapy has specifically flagged this as a dose-delivery concern.
The COMPPARE Trial and Ongoing Evidence
Beyond PARTIQoL, a large prospective (but non-randomized) study called COMPPARE enrolled over 2,500 men across 51 facilities between 2018 and 2022, with about 1,500 treated with proton therapy and about 1,000 with IMRT. Early results comparing patient-reported bowel urgency and frequency at two years, as well as clinician-reported gastrointestinal toxicity and three-year freedom from biochemical progression, are beginning to emerge. Because COMPPARE is not randomized, it cannot definitively settle the question of superiority, but its size and prospective design make it a valuable complement to PARTIQoL. It also captures a wider range of treatment approaches, including hypofractionation and rectal spacer use at the treating physician’s discretion, which makes its findings more reflective of real-world practice.
The Particle Therapy Co-Operative Group’s Genitourinary Subcommittee has published a consensus statement acknowledging that multiple prospective and retrospective studies document the efficacy and safety of proton therapy for localized prostate cancer, while also noting the need to address cost-effectiveness and patient selection criteria. The consensus is not that protons are better, but that they are a reasonable option. Which patients stand to benefit most remains an open question.
Who Might Benefit Most From Proton Therapy
Given the current evidence, a few patient profiles emerge as potentially stronger candidates for proton therapy. Younger men with decades of life ahead face a longer window during which secondary cancers could develop, and the consistent finding that protons reduce whole-body radiation exposure is most meaningful for them. Men with metal hip implants face practical beam-planning challenges that protons handle more gracefully. Men who need pelvic nodal irradiation may benefit from the reduced integral dose to bowel and bone marrow. And men who place an extremely high value on minimizing any particular side effect, even at considerable financial cost, may find the marginal differences in some retrospective analyses worth pursuing.
For the average man with low- or intermediate-risk prostate cancer, without complicating anatomy and with a typical life expectancy, the best available evidence says he can expect the same cancer control and the same quality of life whether he chooses proton therapy or IMRT. The difference will show up most clearly on the bill.